All preg-nancies | RA | PsA | SpA | JIA | UA | SLE | PAPS – aPL carriers | UCTD | pSS | SSc | IIM | SV | Anti-Ro/SSA carriers | |
Number of pregnancies | 866 | 122 | 69 | 47 | 31 | 12 | 169 | 135 | 136 | 41 | 28 | 20 | 38 | 18 |
Oral Glucocorticoids | 244 (28.2%) | 52 (42.6%) | 15 (21.7%) | 6 (12.8%) | 5 (16.1%) | 4 (33.3%) | 84 (49.7%) | 15 (11.1%) | 24 (17.6%) | 8 (19.5%) | 4 (14.3%) | 12 (60%) | 12 (31.6%) | 3 (16.7%) |
NSAIDs (regular use) | 10 (1.2%) | 1 (0.8%) | 2 (2.9%) | 4 (8.5%) | 0 (0%) | 1 (8.3%) | 1 (0.6%) | 1 (0.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Hydroxychloroquine | 388 (44.8%) | 59 (48.4%) | 4 (5.8%) | 1 (2.1%) | 5 (16.1%) | 3 (25%) | 136 (80.5%) | 40 (29.6%) | 82 (60.3%) | 30 (73.2%) | 6 (21.4%) | 10 (50%) | 1 (2.6%) | 11 (61.1%) |
csDMARDs * | 85 (9.8%) | 4 (3.3%) | 5 (5.8%) | 1 (2.1%) | 1 (3.2%) | 0 (0%) | 46 (27.2%) | 4 (3%) | 3 (2.2%) | 0 (0%) | 4 (14.3%) | 10 (50%) | 7 (18.4%) | 0 (0%) |
bDMARDs * | 122 (14.1%) | 46 (37.7%) | 27 (39.1%) | 17 (36.2%) | 12 (38.7%) | 5 (41.7%) | 7 (4.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5%) | 7 (18.4%) | 0 (0%) |
tsDMARDs | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Adjunct treatment | ||||||||||||||
LDASA | 566 (58.4%) | 42 (34.4%) | 27 (39.1%) | 14 (29.8%) | 10 (32.3%) | 7 (58.3%) | 123 (72.8%) | 115 (85.2%) | 83 (61%) | 22 (53.7%) | 20 (71.4%) | 12 (60%) | 23 (60.5%) | 8 (44.4%) |
Heparin | 220 (25.4%) | 10 (8.2%) | 6 (8.7%) | 2 (4.3%) | 1 (3.2%) | 1 (8.3%) | 53 (31.4%) | 107 (79.3%) | 23 (16.9%) | 5 (12.2%) | 1 (3.6%) | 1 (5%) | 8 (21.1%) | 2 (11.1%) |
Folic acid | 694 (80.1%) | 101 (82.8%) | 53 (76.8%) | 34 (72.3%) | 25 (80.6%) | 7 (58.3%) | 136 (80.5%) | 111 (82.2%) | 108 (79.4%) | 34 (82.9%) | 24 (85.7%) | 15 (75%) | 32 (84.2%) | 14 (77.8%) |
Vitamin D | 521 (60.2%) | 69 (56.6%) | 34 (49.3%) | 25 (53.2%) | 14 (45.2%) | 7 (58.3%) | 116 (68.6%) | 78 (57.8%) | 83 (61%) | 27 (65.9%) | 17 (60.7%) | 15 (75%) | 28 (73.7%) | 8 (44.4%) |
*See online supplemental table 6 for details.
bDMARDs, biological DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs; IIM, idiopathic inflammatory myopathies; JIA, juvenile idiopathic arthritis; LDASA, low-dose acetylsalicylic acid; NSAIDs, non-steroidal anti-inflammatory drugs; PAPS, primary antiphospholipid syndrome; PsA, psoriatic arthritis; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; SSc, systemic sclerosis; SV, systemic vasculitis; tsDMARDs, targeted synthetic DMARDs; UA, undifferentiated arthritis; UCTD, undifferentiated connective tissue disease.